Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Lab Med. 2023 Mar 1;43(2):153-166. doi: 10.3343/alm.2023.43.2.153. Epub 2022 Oct 25.
Despite the popularity of the NeoBase 2 Non-derivatized MSMS assay (PerkinElmer, Turku, Finland), there are no reports of its comprehensive evaluation, including the ability to distinguish transient tyrosinemia of the newborn (TTN) from tyrosinemia type 1 (TYR 1) using succinylacetone (SUAC). No newborn screening (NBS) cutoffs for preterm neonates in the Korean population have been suggested. We evaluated the NeoBase 2 assay and identified analytes requiring different cutoffs in preterm neonates.
Residual NBS dried blood spot samples and proficiency testing (PT) materials of the Newborn Screening Quality Assurance Program and the Korean Association of External Quality Assessment Service were used. Precision, accuracy, limit of detection (LOD), lower limit of quantification (LLOQ), linearity, recovery, carryover, and performance of SUAC were evaluated. Cutoffs were determined, and analytes requiring different cutoffs in preterm neonates were investigated.
Mean CVs for within-run and between-day precision were within 15%. Accuracy analysis indicated high agreement with in-house derivatized assay results and results of other PT participants. All analytes demonstrated acceptable LOD, LLOQ, and linearity. Recoveries were acceptable, except for SUAC. Carryover was negligible. Cutoffs were established for all analytes; Tyr, adenosine, and C20:0-lysophosphatidylcholine required different cutoffs in preterm neonates. Differential diagnosis of TYR 1 and TTN was successful with simultaneous Tyr and SUAC measurement.
The NeoBase 2 assay demonstrated satisfactory performance. The additional analytes provide a wider diagnostic coverage, and the simultaneous measurement of Tyr and SUAC is efficient in excluding TYR 1. The new cutoffs for preterm neonates may decrease false-positive rates, without compromising diagnostic sensitivity.
尽管 NeoBase 2 非衍生 MSMS 测定法(PerkinElmer,图尔库,芬兰)广受欢迎,但尚无关于其全面评估的报道,包括使用丁二酮肟(SUAC)区分新生儿暂态酪氨酸血症(TTN)与酪氨酸血症 1 型(TYR 1)的能力。尚未提出韩国人群中早产儿的新筛截止值。我们评估了 NeoBase 2 测定法,并确定了早产儿中需要不同截止值的分析物。
使用新生儿筛查质量保证计划和韩国外部质量评估服务协会的剩余新筛干血斑样本和能力验证(PT)材料。评估了精密度、准确度、检测限(LOD)、定量下限(LLOQ)、线性、回收率、携带污染和 SUAC 的性能。确定了截止值,并研究了早产儿中需要不同截止值的分析物。
批内和日间精密度的平均 CV 均在 15%以内。准确度分析表明与内部衍生测定结果和其他 PT 参与者的结果高度一致。所有分析物均表现出可接受的 LOD、LLOQ 和线性。除 SUAC 外,回收率可接受。携带污染可忽略不计。为所有分析物建立了截止值;酪氨酸、腺苷和 C20:0-溶血磷脂酰胆碱在早产儿中需要不同的截止值。同时测量 Tyr 和 SUAC 可成功进行 TYR 1 和 TTN 的鉴别诊断。
NeoBase 2 测定法表现出令人满意的性能。额外的分析物提供了更广泛的诊断覆盖范围,同时测量 Tyr 和 SUAC 可有效排除 TYR 1。早产儿的新截止值可能会降低假阳性率,而不会影响诊断灵敏度。